Titan Pharmaceuticals (NASDAQ:TTNP) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 15th.
Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Monday, April 1st. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.20). Titan Pharmaceuticals had a negative net margin of 136.32% and a negative return on equity of 355.20%. The company had revenue of $1.24 million during the quarter, compared to the consensus estimate of $0.40 million. On average, analysts expect Titan Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ TTNP traded up $0.01 during trading on Thursday, hitting $1.65. The company’s stock had a trading volume of 65,400 shares, compared to its average volume of 991,374. The company has a quick ratio of 3.49, a current ratio of 3.85 and a debt-to-equity ratio of 0.55. The company has a market cap of $22.25 million, a P/E ratio of -2.09 and a beta of 0.67. Titan Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $6.90.
Separately, ValuEngine raised Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 2nd.
A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by 256.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 341,474 shares of the specialty pharmaceutical company’s stock after buying an additional 245,565 shares during the period. Geode Capital Management LLC owned approximately 2.63% of Titan Pharmaceuticals worth $76,000 as of its most recent SEC filing. 24.17% of the stock is currently owned by hedge funds and other institutional investors.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
See Also: What is the Fibonacci sequence?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.